10 research outputs found
Fatty acids in formulae for term infants:Compliance of present recommendations with the actual human milk fatty acid composition of geographically different populations
Effect of an increased intake of alpha-linolenic acid and group nutritional education on cardiovascular risk factors: the Mediterranean Alpha-linolenic Enriched Groningen Dietary Intervention (MARGARIN) study
BACKGROUND: The effect of long-term increased intakes of alpha-linolenic acid (ALA; 18:3n-3) on cardiovascular risk factors is unknown. OBJECTIVES: Our objectives were to assess the effect of increased ALA intakes on cardiovascular risk factors and the estimated risk of ischemic heart disease (IHD) at 2 y and the effect of nutritional education on dietary habits. DESIGN: Subjects with multiple cardiovascular risk factors (124 men and 158 women) were randomly assigned in a double-blind fashion to consume a margarine rich in either ALA [46% linoleic acid (LA; 18:2n-6) and 15% ALA; n = 114] or LA (58% LA and 0.3% ALA; n = 168). An intervention group (n = 110; 50% ALA) obtained group nutritional education, and a control group (n = 172; 34% ALA) received a posted leaflet containing the standard Dutch dietary guidelines. RESULTS: Average ALA intakes were 6.3 and 1.0 g/d in the ALA and LA groups, respectively. After 2 y, the ALA group had a higher ratio of total to HDL cholesterol (+0.34; 95% CI: 0.12, 0.56), lower HDL cholesterol (-0.05 mmol/L; -0.10, 0), higher serum triacylglycerol (+0.24 mmol/L; 0.02, 0.46), and lower plasma fibrinogen (-0.18 g/L; -0.31, -0.04; after 1 y) than did the LA group (adjusted for baseline values, sex, and lipid-lowering drugs). No significant difference existed in 10-y estimated IHD risk. After 2 y, the intervention group had lower saturated fat intakes and higher fish intakes than did the control group. CONCLUSIONS: Increased ALA intakes decrease the estimated IHD risk to an extent similar to that found with increased LA intakes. Group nutritional education can effectively increase fish intake. Record 4 of 4 - SilverPlatter MEDLINE(R)
Curacao patients with coronary artery disease have a higher prevalence of the HFE C282Y mutation
Curacao patients with coronary artery disease have a higher prevalence of the HFE C282Y mutation
Curacao patients with coronary artery disease have a higher prevalence of the HFE C282Y mutation
Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group
A single-agent dose-escalating Phase I and pharmacological study of the
polyamine synthesis inhibitor SAM 486A was performed. A dosing regimen of
four weekly infusions followed by 2 weeks off therapy was studied. Fifty
patients were entered into the study. Dose levels studied were 1.25, 2.5,
5, 8, 16, 32, 48, 70, 110, 170, 270, and 325 mg/m2/week. Pharmacokinetic
sampling was done on day 1, and trough samples were taken weekly during
the first treatment cycle. Pharmacodynamic sampling was done on days 1 and
22. At 325 mg/m2/week, dose-limiting toxicity was seen (one patient each
with grade 4 febrile neutropenia, grade 3 neurotoxicity, and grade 3
hypotension with syncope and T-wave inversions on electrocardiogram). The
recommended dose for further testing was set at 270 mg/m2/week. Infusion
time was increased from 10 to 180 min due to facial paresthesias and
flushing and somnolence. Drug exposure increased linearly with dose. Mean
+/- SD t1,2 at 70-325 mg/m2 doses was 61.4+/-26.2 h, with a large volume
of distribution at steady state. In peripheral blood leukocytes, a clear
relationship between dose and inhibitory effect on S-adenosylmethionine
decarboxylase or changes in intracellular polyamine pools was not
recorded. SAM 486A can be administered safely using a dosing regimen of
four weekly infusions followed by 2 weeks off therapy. The recommended
dose for Phase II studies using this regimen is 270 mg/m2/week